|
|
|
|||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
Corrigendum
for Mercader et al.,
First published online September 12, 2006
doi: 10.1242/10.1242/dev.02594
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Corrigendum |
Nadia Mercader, Sabine Fischer and Carl J. Neumann Development 133, 2805-2815.
There were mistakes in the Materials and methods `Treatment with DEAB, SU5402' section on p. 2806 of this paper. The whole section should therefore be replaced with the following.
4-Diethylaminobenzaldehyde (DEAB) (Fluka) and the FGF receptor inhibitor SU5402 (Calbiochem) were dissolved in dimethylsulfoxide (DMSO) and used at a concentration of 10 µM and 16 µM, respectively. DEAB treatment was performed from 30% epiboly onwards. Incubations were carried out in the dark at 28°C.
The authors apologise to readers for the mistakes.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||